Novel Alzheimer's disease Therapy to Slow Cognitive Decline?

MAY 01, 2017
Amy Jacob


At AAN 2017, Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics, spoke with MD Magazine about his team’s two phase 3 studies in Alzheimer’s disease that studied a “well-established” target called the receptor for advanced glycation endproducts (RAGE).  


Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.